6 Apr
2021

Pharma companies must factor tough standing requirements into IPR strategies

Rules on standing pose tough choices for would-be IPR petitioners, as Argentum Pharmaceuticals’ recent experiences suggest.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth